F-star Biotechnology Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From F-star Biotechnology Limited
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
- Drug Discovery Tools
- Other Names / Subsidiaries
- F-star Alpha Ltd.
- F-star GmbH
- F-star Therapeutics